OBJECTIVE: This study aimed to evaluate the possible safety and effectiveness of infliximab in patients with active scleritis. STUDY DESIGN: Prospective, nonrandomized, open-label pilot study (Protocol No. 04-EI-0065). PARTICIPANTS: Five patients with active anterior scleritis. METHODS: This single-centre, pilot study of infliximab for the treatment of active anterior scleritis was conducted at the National Eye Institute, National Institutes of Health, between 2003 and 2007. Scleritis patients with active disease who had used at least 1 conventional immunosuppressive agent in the past were included. Primary outcome was a 2-step decrease in scleral inflammation within 14 weeks. Patients received infliximab (5 mg/kg) at baseline, at weeks 2 and 6, and every 4 weeks through week 30, after which the infusion interval was increased (week 36, 48). RESULTS: All patients met the primary outcome by achieving quiescence of their active scleritis by week 14 with no additional immunosuppressives. However, after 14 weeks 1 patient developed new-onset intraocular inflammation that did not respond to reinduction and was terminated from the study. Side effects attributable to infliximab included ear infection with transient decreased hearing, urinary tract infection, lower respiratory tract infection, and facial rash in 1 patient and urinary tract infection, diarrhea, upper respiratory tract infection, nasal congestion and headache, mouth sores, head tremor, and occasional numbness and tingling in extremities in another patient, all of which resolved spontaneously or with appropriate treatment. CONCLUSIONS: Infliximab may be considered as a viable option in treating patients with active scleritis; however, patients should be monitored closely for potentially serious side effects.
OBJECTIVE: This study aimed to evaluate the possible safety and effectiveness of infliximab in patients with active scleritis. STUDY DESIGN: Prospective, nonrandomized, open-label pilot study (Protocol No. 04-EI-0065). PARTICIPANTS: Five patients with active anterior scleritis. METHODS: This single-centre, pilot study of infliximab for the treatment of active anterior scleritis was conducted at the National Eye Institute, National Institutes of Health, between 2003 and 2007. Scleritispatients with active disease who had used at least 1 conventional immunosuppressive agent in the past were included. Primary outcome was a 2-step decrease in scleral inflammation within 14 weeks. Patients received infliximab (5 mg/kg) at baseline, at weeks 2 and 6, and every 4 weeks through week 30, after which the infusion interval was increased (week 36, 48). RESULTS: All patients met the primary outcome by achieving quiescence of their active scleritis by week 14 with no additional immunosuppressives. However, after 14 weeks 1 patient developed new-onset intraocular inflammation that did not respond to reinduction and was terminated from the study. Side effects attributable to infliximab included ear infection with transient decreased hearing, urinary tract infection, lower respiratory tract infection, and facial rash in 1 patient and urinary tract infection, diarrhea, upper respiratory tract infection, nasal congestion and headache, mouth sores, head tremor, and occasional numbness and tingling in extremities in another patient, all of which resolved spontaneously or with appropriate treatment. CONCLUSIONS:Infliximab may be considered as a viable option in treating patients with active scleritis; however, patients should be monitored closely for potentially serious side effects.
Authors: P P Sfikakis; P H Kaklamanis; A Elezoglou; N Katsilambros; P G Theodossiadis; S Papaefthimiou; N Markomichelakis Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: D W Hommes; B Oldenburg; A A van Bodegraven; R A van Hogezand; D J de Jong; M J L Romberg-Camps; J van der Woude; G Dijkstra Journal: Neth J Med Date: 2006 Jul-Aug Impact factor: 1.422
Authors: S Mascheretti; J Hampe; T Kühbacher; H Herfarth; M Krawczak; U R Fölsch; S Schreiber Journal: Pharmacogenomics J Date: 2002 Impact factor: 3.550
Authors: H Nida Sen; Eric B Suhler; Shadi Q Al-Khatib; Ali R Djalilian; Robert B Nussenblatt; Ronald R Buggage Journal: Ophthalmology Date: 2003-09 Impact factor: 12.079
Authors: Annie Joseph; Dev Raj; Harminder S Dua; Pauline T Powell; Peter C Lanyon; Richard J Powell Journal: Ophthalmology Date: 2003-07 Impact factor: 12.079
Authors: Conor C Murphy; William H Ayliffe; Anthony Booth; David Makanjuola; Peter A Andrews; David Jayne Journal: Ophthalmology Date: 2004-02 Impact factor: 12.079
Authors: Ronald R Buggage; Grace Levy-Clarke; Hatice N Sen; Roxana Ursea; Sunil K Srivastava; Eric B Suhler; Chandra Altemare; Gisela Velez; Jack Ragheb; Chi-Chao Chan; Robert B Nussenblatt; Alison T Bamji; Puspha Sran; Thomas Waldmann; Darby J S Thompson Journal: Ocul Immunol Inflamm Date: 2007 Mar-Apr Impact factor: 3.070
Authors: Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani Journal: Int Ophthalmol Date: 2015-08-29 Impact factor: 2.031
Authors: H Nida Sen; Amit A Sangave; Debra A Goldstein; Eric B Suhler; Denise Cunningham; Susan Vitale; Robert B Nussenblatt Journal: Ophthalmology Date: 2010-11-20 Impact factor: 12.079
Authors: Jared E Knickelbein; William R Tucker; Nirali Bhatt; Karen Armbrust; David Valent; Dominic Obiyor; Robert B Nussenblatt; H Nida Sen Journal: Am J Ophthalmol Date: 2016-09-20 Impact factor: 5.258
Authors: Muhammad Amir Bin Ismail; Rachel Hui Fen Lim; Helen Mi Fang; Elizabeth Poh Ying Wong; Ho Su Ling; Wee Kiak Lim; Stephen C Teoh; Rupesh Agrawal Journal: J Ophthalmic Inflamm Infect Date: 2017-02-15